Discontinuation timing of GLP-1 receptor agonists before colonoscopy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study compares two discontinuation intervals of GLP-1 receptor agonists prior to colonoscopy to see which approach yields better bowel preparation. The trial focuses on adults aged 18-70 scheduled for total colonoscopy and evaluates bowel cleanliness and the potential need for a repeat procedure. It considers the pharmacologic effects of GLP-1 RAs on gastric emptying and motility. Participants who are not using GLP-1 RAs will also be eligible to contribute comparative data. The study is conducted at Fu Jen Catholic University Hospital in New Taipei, Taiwan, and is sponsored by the lead institution.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Inclusion Criteria for non GLP-1 user:

  * Individuals who are scheduled to undergo total colonoscopy for any reasons
  * Age between 18 to 70 years.
  * ECOG Performance status is 0 or 1.
  * Written consent to participate in the study has been obtained.
  * Outpatient department patient
  * Stop at least 3 days if current using medications that promote or inhibit gastrointestinal motility.

Exclusion Criteria:

* • Presence of severe comorbid conditions that preclude the safe performance of colonoscopy (e.g., unstable angina, recent myocardial infarction, decompensated heart failure, chronic respiratory disease, or bleeding diathesis).

  * History of prior gastric, small bowel, or colorectal segmental resection (patients with isolated appendectomy are eligible).
  * Family history of hereditary colorectal cancer syndromes.
  * Current or prior diagnosis of inflammatory bowel disease.
  * Known colorectal polyposis syndromes.
  * Any other condition deemed inappropriate for study participation at the discretion of the treating physician.
  * Body mass index (BMI) \> 40 kg/m².
  * Diagnosis of liver cirrhosis.
  * Diagnosis of Parkinson's disease.
  * Diagnosis of dementia.
  * Use of tricyclic antidepressants or opioid medications for more than 3 months.

Where it's running

• Fjuh
  New Taipei, Taiwan, Taiwan Recruiting

Study contacts

• Study coordinator: Kuan I Sung
• Email: ioudanny520@hotmail.com
• Phone: +886928139643

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ubiquinol to See if It Reduces Fatigue for Adults Using GLP-1 Weight-Loss Meds

  A daily ubiquinol supplement is tested to see if it lowers fatigue and helps keep muscle strength in adults taking GLP-1 weight-loss medicines.

  Recruiting StudySetGo · Glasgow · NCT07789106

• Should GLP-1 receptor agonists be stopped a week before an endoscopy?

  A one-week pause of long-acting GLP-1 receptor agonists is being tested to see if it improves gastric prep quality and reduces the need for repeat endoscopy in adults undergoing EGD.

  Recruiting Phase 3 Fu Jen Catholic University Hospital · New Taipei City, Taiwan · NCT07736911

• GLP-1 receptor agonists and dry eye in adults with type 2 diabetes and obesity

  This study tests whether GLP-1 receptor agonists affect dry eye disease in adults with type 2 diabetes and obesity.

  Recruiting Attikon Hospital · Athens · NCT07605572

• Lifestyle change program with GLP-1 medication users

  This trial tests whether the Noom digital lifestyle program helps adults on GLP-1 medications improve eating, activity, and weight-related health.

  Recruiting University of Massachusetts, Worcester · Worcester, Massachusetts · NCT07481305

• A nutritional supplement to fill nutrient gaps and support gut health for people taking GLP-1 medications.

  This study will test whether a daily nutritional supplement can reduce nutrient gaps and improve the gut microbiome in adults who are using GLP-1 receptor agonist medications.

  Recruiting Athletic Greens International · Santa Monica, California · NCT07437911

• Semaglutide's effects on heart and muscle mass

  This project will use MRI scans and strength tests over 12 months to see if semaglutide changes body and heart muscle in adults starting the medication.

  Recruiting University of Alberta · Edmonton, Alberta · NCT07272837

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.